Completed PHASE1 INTERVENTIONAL 1-arm NCT03802955

Study of ADG106 With Advanced or Metastatic Solid Tumors and/or Non-Hodgkin Lymphoma

A Phase Ⅰ Study of ADG106 Administered in Patients With Advanced or Metastatic Solid Tumors and/or Non-Hodgkin Lymphoma

Sponsor: Adagene (Suzhou) Limited

Conditions Non-Hodgkin Lymphoma Solid Tumor

Interventions ADG106

Updated 10 times since 2019 Last updated: Apr 20, 2023 Started: Dec 20, 2018 Primary completion: Nov 1, 2021 Completion: Nov 1, 2021

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03802955, this PHASE1 trial focuses on Non-Hodgkin Lymphoma and Solid Tumor and remains completed. Sponsored by Adagene (Suzhou) Limited, it has been updated 10 times since 2018, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

10 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
May 2023 — Jul 2024 [monthly]

Completed PHASE1

Status: Active Not Recruiting → Completed
Nov 2022 — May 2023 [monthly]

Active Not Recruiting PHASE1
Sep 2022 — Nov 2022 [monthly]

Active Not Recruiting PHASE1

▶ Show 5 earlier versions

Feb 2022 — Sep 2022 [monthly]

Active Not Recruiting PHASE1
Jun 2021 — Feb 2022 [monthly]

Active Not Recruiting PHASE1

Status: Recruiting → Active Not Recruiting
Mar 2021 — Jun 2021 [monthly]

Recruiting PHASE1
Jan 2021 — Mar 2021 [monthly]

Recruiting PHASE1
Feb 2019 — Jan 2021 [monthly]

Recruiting PHASE1

First recorded

Dec 2018

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Adagene (Suzhou) Limited

Data source: Adagene Inc

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Guangzhou, China
• Shanghai, China